These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8140563)

  • 21. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase III trials of toremifene vs tamoxifen.
    Gams R
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):23-8. PubMed ID: 9165503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical studies--what is the putting of the question?].
    Guttenberger R
    Strahlenther Onkol; 1999 Apr; 175 Suppl 1():14-6. PubMed ID: 10230452
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical trial design in hepatocellular carcinoma.
    Johnson PJ; Billingham LJ
    Best Pract Res Clin Gastroenterol; 2005 Feb; 19(1):119-27. PubMed ID: 15757808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Are phase II or phase II antidepressive drug studies still feasible considering currently required inclusion and exclusion criteria?].
    Steckler T; Hosten K; Müller-Oerlinghausen B
    Nervenarzt; 1993 Mar; 64(3):204-7. PubMed ID: 8479593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
    Sakamoto J; Morita S
    Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and scale-up of a microsphere protein delivery system.
    Tracy MA
    Biotechnol Prog; 1998; 14(1):108-15. PubMed ID: 9496675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004.
    Buoen C; Bjerrum OJ; Thomsen MS
    J Clin Pharmacol; 2005 Oct; 45(10):1123-36. PubMed ID: 16172177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
    [No Abstract]   [Full Text] [Related]  

  • 35. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
    Freidlin B; Breathnach OS; Johnson BE
    Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Phase I clinical trials].
    Jaillon P
    Presse Med; 2001 May 26-Jun 2; 30(19):952-5. PubMed ID: 11433726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics/pharmacodynamics during phase II and III studies: population kinetics and the kinetic screen.
    Balant LP; Gex-Fabry M
    Boll Chim Farm; 1993 Jun; 132(6):210-1. PubMed ID: 8104425
    [No Abstract]   [Full Text] [Related]  

  • 39. [Necessity of clinically controlled studies for the development of new drugs].
    Lüthy E; Joyce CR
    Ther Umsch; 1971 Apr; 28(4):246-9. PubMed ID: 4930184
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical study of new blood products].
    Salmi R; Perez P
    Transfus Clin Biol; 2000 Jun; 7(3):251-2. PubMed ID: 10919212
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.